Header cover image

Chinese (SSE) Pharma Industry Analysis

UpdatedJun 15, 2024
DataAggregated Company Financials
Companies220
  • 7D-1.1%
  • 3M-4.5%
  • 1Y-12.5%
  • YTD-9.8%

The Pharma is pretty flat in the last 7 days, but Haisco Pharmaceutical Group has stood out, gaining 6.1%. As for the longer term, the industry has declined 12% in the last year. Earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the Chinese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 15 Jun 2024CN¥2.5tCN¥805.5bCN¥74.6b27.7x33.6x3.1x
Mon, 13 May 2024CN¥2.8tCN¥821.6bCN¥77.5b31.9x36.2x3.4x
Wed, 10 Apr 2024CN¥2.6tCN¥828.5bCN¥78.2b28.7x33.4x3.1x
Fri, 08 Mar 2024CN¥2.5tCN¥831.9bCN¥80.7b26.2x31.2x3x
Sun, 04 Feb 2024CN¥2.2tCN¥831.4bCN¥79.9b23.4x28x2.7x
Tue, 02 Jan 2024CN¥2.8tCN¥827.8bCN¥79.7b31x35.3x3.4x
Thu, 30 Nov 2023CN¥2.9tCN¥819.4bCN¥78.7b31.6x36.8x3.5x
Sat, 28 Oct 2023CN¥2.8tCN¥825.1bCN¥78.8b31.2x35x3.3x
Mon, 25 Sep 2023CN¥2.7tCN¥824.8bCN¥78.6b31.2x34.8x3.3x
Wed, 23 Aug 2023CN¥2.6tCN¥815.9bCN¥77.6b30.4x33.5x3.2x
Fri, 21 Jul 2023CN¥2.7tCN¥811.0bCN¥76.9b31.3x35.6x3.4x
Sun, 18 Jun 2023CN¥2.9tCN¥809.7bCN¥76.5b31.8x37.4x3.5x
Tue, 16 May 2023CN¥3.0tCN¥809.1bCN¥76.5b32.8x38.6x3.6x
Thu, 13 Apr 2023CN¥3.0tCN¥797.0bCN¥91.2b34.1x32.7x3.7x
Sat, 11 Mar 2023CN¥2.9tCN¥778.0bCN¥83.4b37.3x34.5x3.7x
Mon, 06 Feb 2023CN¥2.9tCN¥774.7bCN¥83.1b36x35.3x3.8x
Wed, 04 Jan 2023CN¥2.8tCN¥771.4bCN¥82.1b34.5x33.6x3.6x
Fri, 02 Dec 2022CN¥2.8tCN¥767.8bCN¥81.9b36.2x34.3x3.7x
Sun, 30 Oct 2022CN¥2.6tCN¥766.6bCN¥81.9b33.6x31.5x3.4x
Tue, 27 Sep 2022CN¥2.3tCN¥760.3bCN¥79.5b29.1x28.8x3x
Thu, 25 Aug 2022CN¥2.6tCN¥754.1bCN¥81.1b30.5x31.5x3.4x
Sat, 23 Jul 2022CN¥2.7tCN¥744.7bCN¥81.0b31.4x33.9x3.7x
Mon, 20 Jun 2022CN¥2.7tCN¥739.6bCN¥82.0b32.1x33.1x3.7x
Wed, 18 May 2022CN¥2.6tCN¥740.3bCN¥81.7b32.5x31.6x3.5x
Fri, 15 Apr 2022CN¥2.7tCN¥724.5bCN¥76.1b33.2x35.2x3.7x
Sun, 13 Mar 2022CN¥2.9tCN¥727.1bCN¥77.5b34x36.9x3.9x
Tue, 08 Feb 2022CN¥2.7tCN¥721.5bCN¥73.6b32.3x37.3x3.8x
Thu, 06 Jan 2022CN¥3.1tCN¥720.5bCN¥73.8b37.6x42.3x4.3x
Sat, 04 Dec 2021CN¥3.0tCN¥718.2bCN¥73.3b32.1x41.1x4.2x
Mon, 01 Nov 2021CN¥2.8tCN¥714.7bCN¥70.6b29x39.5x3.9x
Wed, 29 Sep 2021CN¥2.9tCN¥702.7bCN¥71.2b31.4x40.2x4.1x
Fri, 27 Aug 2021CN¥2.8tCN¥702.6bCN¥71.1b29.8x38.8x3.9x
Sat, 03 Jul 2021CN¥3.2tCN¥697.2bCN¥70.2b32.4x46.1x4.6x
Price to Earnings Ratio

46.1x


Total Market Cap: CN¥3.2tTotal Earnings: CN¥70.2bTotal Revenue: CN¥697.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Chinese Pharma Industry Price to Earnings3Y Average 35.7x202220232024
Current Industry PE
  • Investors are relatively neutral on the Chinese Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 35.7x.
  • The 3-year average PS ratio of 3.6x is higher than the industry's current PS ratio of 3.1x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 2.0% per year over the last three years.
  • Revenues for these companies have grown 4.9% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Chinese Healthcare industry?

CN Market0.061%
Healthcare-0.73%
Pharma-1.12%
Pharma-1.12%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
2653 Haisco Pharmaceutical GroupCN¥33.209.3%
+CN¥3.1b
40.2%PE102.2x
2294 Shenzhen Salubris PharmaceuticalsCN¥28.544.7%
+CN¥1.4b
-12.8%PE54.7x
603520 Zhejiang Starry PharmaceuticalLtdCN¥10.190.4%
+CN¥990.9m
-40.0%PE95.2x
766 Tonghua Golden-Horse Pharmaceutical Industry CoLtdCN¥17.286.1%
+CN¥966.5m
260.8%PE380.1x
2422 Sichuan Kelun PharmaceuticalCN¥32.361.5%
+CN¥747.7m
7.4%PE19.3x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

603520

CN¥10.19

Zhejiang Starry PharmaceuticalLtd

7D

0.4%

1Y

-40.0%

538

CN¥52.82

Yunnan Baiyao GroupLtd

7D

-2.4%

1Y

-1.0%

999

CN¥46.05

China Resources Sanjiu Medical & Pharmaceutical

7D

-7.4%

1Y

-1.3%

423

CN¥65.34

Dong-E-E-JiaoLtd

7D

-6.4%

1Y

33.2%

688506

CN¥196.94

Sichuan Biokin PharmaceuticalLtd

7D

-4.8%

1Y

153.5%

600196

CN¥23.18

Shanghai Fosun Pharmaceutical (Group)

7D

-3.3%

1Y

-24.6%

688076

CN¥61.40

Jiangsu Sinopep-Allsino Biopharmaceutical

7D

5.7%

1Y

68.0%

2653

CN¥33.20

Haisco Pharmaceutical Group

7D

9.3%

1Y

40.2%